Company shares last traded at $2.20 just a bit higher than $2.04, the 50 day moving average and which is marginally higher than the 200 day moving average of $2.06. The 50 day moving average went up $0.16 or +7.7894% and the 200 day average went up by +6.6482%. Trading volume for Prima BioMed Ltd – American Dep was 42K by the end of trading on Tuesday. Volume was down 77.26% under the stocks average daily volume.
Investors are a little more bearish on shares of Prima BioMed Ltd – American Dep of late if you take a look at the rise in short interest. The company experienced a rise in short interest of 158.71% between September 29, 2017 and October 13, 2017. Short interest grew from 96,337 to 249,235 over that timeframe. With short interest at 249,235 and short average daily volume at 299,932, the short-interest ratio is 1.0 and the percentage of shorted shares is 0.01% as of October 13.
These firms have modified their investment in PBMD. Citadel Advisors LLC grew its holdings by buying 43,435 shares an increase of 181.7% in the quarter. Citadel Advisors LLC now holds 67,345 shares valued at $64,000. The total value of its holdings increased 204.8%.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer. Its lead product candidate is IMP321, a recombinant protein, which is in phase II clinical trials in metastatic breast cancer when used as a chemo-immunotherapy. The company’s other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. It also develops CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The company has collaboration with NEC Corporation and Yamaguchi University. Prima BioMed Ltd. is based in Sydney, Australia..